Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-lipoic acid for the treatment of amyotrophic lateral sclerosis (ALALS)
2005-005152-40Phase 2
Key facts
- Status
- Active
- Start
- Apr 2006
- Countries
- 1
- Sponsor
- AOU Città della Salute e della Scienza di Torino
- Modality
- Small Molecules
- Drugs
- alpha-lipoic acid
- Conditions
- amyotrophic lateral sclerosis (ALS)
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Alpha-lipoic acid with Placebo (2 arms). Started Apr 2006; status: active.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Alpha-lipoic acid
Participants receive alpha-lipoic acid (thioctic acid) for 12 months in a double-blind fashion.
Placebo
Participants receive matching placebo for 12 months in a double-blind fashion.
03
Who it enrols
Adults aged 30–70 years with probable or definite sporadic amyotrophic lateral sclerosis of less than 18 months' duration; exclusion of familial ALS, serious medical conditions, and cancers.
Beyond the preview
Go deeper on 2005-005152-40.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005152-40.